المملكة المتحدة - الإنجليزية - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - aprepitant - oral capsule - 80mg

المملكة المتحدة - الإنجليزية - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - aprepitant - oral capsule - 80mg

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

hepalink usa inc. - fosaprepitant dimeglumine (unii: d35fm8t64x) (aprepitant - unii:1nf15yr6uy) - fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of: - acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (hec) including high-dose cisplatin. - delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (mec). limitations of use - fosaprepitant has not been studied for the treatment of established nausea and vomiting. pediatric use information is approved for merck sharp & dohme corp., a subsidiary of merck & co., inc.’s emend (fosaprepitant) for injection. however, due to merck sharp & dohme corp., a subsidiary of merck & co., inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. fosaprepitant is contraindicated in patients: - who are hypersensitive to any component of the product. hypersensitivity reactions including anaphylactic reactions, flushing, erythema, and dy

اليابان - الإنجليزية - すりの適正使用協議会 RAD-AR Council, Japan

nippon kayaku - aprepitant - white opaque capsule

اليابان - الإنجليزية - すりの適正使用協議会 RAD-AR Council, Japan

nippon kayaku - aprepitant - 80mg white opaque capsule,125mg pale red opaque / white opaque capsule

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - aprepitant -

ماليزيا - الإنجليزية - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

intega sdn. bhd. - aprepitant -

ماليزيا - الإنجليزية - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

intega sdn. bhd. - aprepitant -

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

alchemy health limited - aprepitant 125mg - capsule - 125 mg - active: aprepitant 125mg excipient: gelatin hypromellose iron oxide red microcrystalline cellulose opacode black s-1-17823 poloxamer 407 purified water sodium laurilsulfate sucrose titanium dioxide - in combination with other antiemetic agents, aprepitant is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of: - highly emetogenic cancer chemotherapy - moderately emetogenic cancer chemotherapy

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

alchemy health limited - aprepitant 40mg - capsule - 40 mg - active: aprepitant 40mg excipient: gelatin hypromellose iron oxide yellow microcrystalline cellulose opacode black s-1-17823 poloxamer 407 purified water sodium laurilsulfate sucrose titanium dioxide - in combination with other antiemetic agents, aprepitant is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of: - highly emetogenic cancer chemotherapy - moderately emetogenic cancer chemotherapy